Meta-analysis of Effects of Oral Administration of Chinese Patent Medicine on Major Adverse Cardiovascular and Cerebrovascular Events after PCI

BAI Yang; CHE Fangyuan; YI Wenhui; BAI Ruina; FENG Zhibo; XI Ruixi; YANG Qiaoning; DONG Guoju; SHI Dazhuo; LI Lizhi

doi:10.13288/j.11-2166/r.2018.12.009

您当前的位置：

首页 >

文章列表页 >

Meta-analysis of Effects of Oral Administration of Chinese Patent Medicine on Major Adverse Cardiovascular and Cerebrovascular Events after PCI

更新时间：2021-11-10

- Meta-analysis of Effects of Oral Administration of Chinese Patent Medicine on Major Adverse Cardiovascular and Cerebrovascular Events after PCI
- Journal of Traditional Chinese Medicine Vol. 59, Issue 12, Pages: 1024-1030(2018)
- 作者机构：
  
  1. 中国中医科学院西苑医院
  2. 中国中医科学院研究生院
  3. 北京中医医院顺义医院
  4. 大庆油田总医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2018.12.009
  CLC： R541.4
- Published：2018
- 稿件说明：
移动端阅览
[1]白洋,车方远,易文慧,白瑞娜,冯志博,郗瑞席,杨巧宁,董国菊,史大卓,李立志.加载口服中成药对PCI术后长期主要不良心脑血管事件影响的Meta分析[J].中医杂志,2018,59(12):1024-1030.

BAI Yang, CHE Fangyuan, YI Wenhui, et al. Meta-analysis of Effects of Oral Administration of Chinese Patent Medicine on Major Adverse Cardiovascular and Cerebrovascular Events after PCI[J]. Journal of Traditional Chinese Medicine2018, 59(12): 1024-1030.
[1]白洋,车方远,易文慧,白瑞娜,冯志博,郗瑞席,杨巧宁,董国菊,史大卓,李立志.加载口服中成药对PCI术后长期主要不良心脑血管事件影响的Meta分析[J].中医杂志,2018,59(12):1024-1030. DOI： 10.13288/j.11-2166/r.2018.12.009.

BAI Yang, CHE Fangyuan, YI Wenhui, et al. Meta-analysis of Effects of Oral Administration of Chinese Patent Medicine on Major Adverse Cardiovascular and Cerebrovascular Events after PCI[J]. Journal of Traditional Chinese Medicine2018, 59(12): 1024-1030. DOI： 10.13288/j.11-2166/r.2018.12.009.

摘要

目的系统评价加载口服中成药对经皮冠状动脉介入治疗（PCI）术后长期（6个月及以上）主要不良心脑血管事件的影响。方法检索EMBASE、MEDLINE、Cochrane library、中国知网、中国生物医学文献数据库等11个数据库

纳入关于中成药对PCI术后终点事件影响的随机对照试验。运用Rev Man 5.3和STATA 12.0软件进行meta分析。结果纳入29项研究

共计4684例患者。PCI术后

与单纯常规西药治疗相比

加载口服中成药在主要终点事件[RR=0.44

95%CI（0.32

0.62）

P<0.00001]、心源性死亡[RR=0.34

95%CI（0.15

0.74）

P=0.007]、非致死性心肌梗死[RR=0.37

95%CI（0.24

0.58）

P<0.0001]、再次血运重建[RR=0.43

95%CI（0.31

0.58）

P<0.00001]、脑卒中[RR=0.50

95%CI（0.29

0.87）

P=0.01]、因冠心病再住院[RR=0.59

95%CI（0.46

0.75）

P<0.0001]、心力衰竭率[RR=0.30

95%CI（0.15

0.58）

P=0.0003]方面具有远期疗效优势。结论西医常规治疗基础上加口服中成药

可能降低PCI术后冠心病患者长期主要不良心脑血管事件发生率。

Abstract

Objective To systematically review the efficacy of routine western medicine（ RWM） plus Chinese oral patent medicines for major adverse cardiovascular and cerebrovascular events（ MACCE） during 6 months or longer after percutaneous coronary intervention（ PCI）. Methods Electronic databases

such as EMBase

Medline

Cochrane Library

CNKI

CBM

and other 11 relevant databases

were searched for randomized control trials that compared oral administration of Chinese patent drugs plus RWM with the same RWM（ or plus placebo） in preventing MACCE during 6 months or longer after PCI. The quality of retrieved literature was assessed by methods from Cochrane Handbook. Valid data were extracted and analyzed by meta-analysis using Rev Man5. 3 and STATA12. 0 software. Results A total of 29 trials（ 4684 patients） met the inclusion criteria and were analyzed. Meta-analysis showed that oral administration of Chinese patent drugs plus RWM could significantly reduce the number of primary endpoint（ RR = 0. 44

95% CI: 0. 32

0. 62

0. 00001）

cardiac mortality（ RR = 0. 34

95% CI: 0. 15

. 74

P = 0. 007）

acute myocardial infarction（ RR = 0. 37

95% CI: 0. 24

0. 58

0. 0001）

repeat revascularization（ RR = 0. 43

95% CI: 0. 31

0. 58

0. 00001）

stroke（ RR = 0. 50

95% CI: 0. 29

0. 87

P =0. 01）

readmission for CHD（ RR = 0. 59

95% CI: 0. 46

0. 75

0. 0001）

heart failure（ RR = 0. 30

95%CI: 0. 15

0. 58

P = 0. 0003）. Conclusions Oral administration of Chinese patent medicines may help prevent long-term MACCE after PCI. Caution should be exercised in drawing a definitive conclusion due to the poor methodological quality.

关键词

Keywords

references

查看原文

Views

315

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy of Janus Kinase Inhibitors in Combination with Chinese Herbal Medicine for Rheumatoid Arthritis：A Retrospective Study and A Meta-analysis

Application and Production of Systematic Review and Meta-Analyses of Preclinical Studies in the Field of Traditional Chinese Medicine

A Meta-Analysis on the Efficacy and Safety of Xihuang Pill/Capsule（西黄丸/胶囊） as an Adjuvant to Radio⁃therapy and Chemotherapy in the Treatment of Malignant Digestive Tract Tumors

Clinical Application Guideline for the Treatment of Influenza in Children with Chinese Patent Medicines （2024）

Treating Recurrent Angina Pectoris After Percutaneous Coronary Intervention based on Qi and blood Vessels

Related Author

ZHAN Chenguang

YANG Shengqin

LI Xin

WEN Yu

ZHANG Peng

YAN Xingrui

DU Haifang

WANG Maojie

Related Institution

The Second Clinical Medical College of Guangzhou University of Chinese Medicine

Guangdong Provincial Hospital of Chinese Medicine

Guangdong Provincial Key Laboratory of Clinical Research on TCM Syndromes

National Key Laboratory of TCM Dampness Syndrome （Co-built by Provincial and Ministry-level Institutions）

Zhongshan Hospital of Traditional Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰